Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 2008. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to a share buyback.
- Shares Purchased: 900,000 Ordinary shares.
- Purchase Price: 1,104.46 pence per share.
- Transaction Date: December 2, 2008.
- Treasury Shares Held: 474,194,158 shares (representing 9.13% of total voting rights).
- Shares in Issue: 5,196,550,298 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of the Company's share capital through the cancellation of 900,000 repurchased shares. Consequently, the total number of shares held in Treasury increased to 474,194,158. The filing does not provide comparative data for prior periods regarding financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming the execution of a share buyback and the resulting capital structure.
Key Facts for Investor Verification
- Verify the total cost of the repurchase (900,000 shares at 1,104.46 pence) against the Company's cash position in other filings.
- Confirm the updated total voting rights denominator (5,196,550,298 shares) for disclosure threshold calculations under FSA rules.
- Note that the repurchased shares were cancelled, permanently reducing the issued share count.
- Check subsequent filings for the impact of this buyback on earnings per share (EPS) and return on equity (ROE).